An interventional trial using atezolizumab in canine cancer patients and a detailed analysis of pre-treatment PBMCs, as well as assessment of the intratumoral PD-L1 expression would be necessary to further evaluate the predictive value of our observations. The gene discussed is CD274; the disease is cancer.